Quick Answer
OS Therapies Inc reported Diluted EPS of $0.98 per share (loss) for fiscal year 2025.
OS Therapies Inc Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.98 | +23.4% |
| 2024 | -$1.28 | +12.3% |
| 2023 | -$1.46 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.21 | -16.7% | -10.5% |
| June 30, 2025 | -$0.19 | +26.9% | -5.6% |
| March 31, 2025 | -$0.18 | +28.0% | +0.0% |
| September 30, 2024 | -$0.18 | +52.6% | +30.8% |
| June 30, 2024 | -$0.26 | +44.7% | -4.0% |
| March 31, 2024 | -$0.25 | — | +34.2% |
| September 30, 2023 | -$0.38 | — | +19.1% |
| June 30, 2023 | -$0.47 | — | — |
- OS Therapies Inc showed an increase of +23.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, OS Therapies Inc’s diluted eps has grown by 32.9% (from $1.46 per share (loss) to $0.98 per share (loss)).
- The most recent figure is from OS Therapies Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: